Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Sevelamer in a diabetologist's perspective : A phosphate-binding resin with glucose-lowering potential. / Brønden, A.; Hansen, M.; Sonne, D. P.; Rohde, U.; Vilsbøll, T.; Knop, Filip K.

I: Diabetes, Obesity and Metabolism, Bind 17, Nr. 2, 01.02.2015, s. 116-120.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Brønden, A, Hansen, M, Sonne, DP, Rohde, U, Vilsbøll, T & Knop, FK 2015, 'Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential', Diabetes, Obesity and Metabolism, bind 17, nr. 2, s. 116-120. https://doi.org/10.1111/dom.12355

APA

Brønden, A., Hansen, M., Sonne, D. P., Rohde, U., Vilsbøll, T., & Knop, F. K. (2015). Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential. Diabetes, Obesity and Metabolism, 17(2), 116-120. https://doi.org/10.1111/dom.12355

Vancouver

Brønden A, Hansen M, Sonne DP, Rohde U, Vilsbøll T, Knop FK. Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential. Diabetes, Obesity and Metabolism. 2015 feb. 1;17(2):116-120. https://doi.org/10.1111/dom.12355

Author

Brønden, A. ; Hansen, M. ; Sonne, D. P. ; Rohde, U. ; Vilsbøll, T. ; Knop, Filip K. / Sevelamer in a diabetologist's perspective : A phosphate-binding resin with glucose-lowering potential. I: Diabetes, Obesity and Metabolism. 2015 ; Bind 17, Nr. 2. s. 116-120.

Bibtex

@article{9601088c9d2b4a2488d8a9a170de71e0,
title = "Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential",
abstract = "Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.",
keywords = "Bile acid sequestrant, Chronic kidney disease, Diabetes, HbA1c, Phosphate resin",
author = "A. Br{\o}nden and M. Hansen and Sonne, {D. P.} and U. Rohde and T. Vilsb{\o}ll and Knop, {Filip K.}",
note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons Ltd.",
year = "2015",
month = feb,
day = "1",
doi = "10.1111/dom.12355",
language = "English",
volume = "17",
pages = "116--120",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Sevelamer in a diabetologist's perspective

T2 - A phosphate-binding resin with glucose-lowering potential

AU - Brønden, A.

AU - Hansen, M.

AU - Sonne, D. P.

AU - Rohde, U.

AU - Vilsbøll, T.

AU - Knop, Filip K.

N1 - Publisher Copyright: © 2014 John Wiley & Sons Ltd.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.

AB - Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.

KW - Bile acid sequestrant

KW - Chronic kidney disease

KW - Diabetes

KW - HbA1c

KW - Phosphate resin

UR - http://www.scopus.com/inward/record.url?scp=84921436822&partnerID=8YFLogxK

U2 - 10.1111/dom.12355

DO - 10.1111/dom.12355

M3 - Review

C2 - 25041567

AN - SCOPUS:84921436822

VL - 17

SP - 116

EP - 120

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -

ID: 305734761